Plain-English translation of NCT07328945 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing a personalized approach to treating advanced non-small cell lung cancer. Doctors will take a small sample of your tumor and test it against various cancer drugs in the lab to predict which treatment will work best for you. The goal is to find a more effective way to match patients with the right medication based on their individual tumor.
Many patients with advanced lung cancer don't respond well to standard treatments because each person's cancer is different. This study aims to solve that problem by using tumor samples to predict which treatment is most likely to help each individual patient, rather than using a one-size-fits-all approach.
You likely qualify if…
You likely don't qualify if…
You will have your tumor sampled (either from a procedure or existing tissue), and the lab will test it against different cancer drugs to see which ones your cancer responds to best. Based on those results and other genetic information, your doctor will recommend the treatment most likely to help you. You'll then receive that treatment while the study team monitors your response through imaging scans, blood tests, and regular follow-up visits over time.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
China
Sponsor
Shanghai Pulmonary Hospital, Shanghai, China
Enrollment target
~250 participants
Started
December 2023
Primary completion
January 2027
Age range
18 Years – 80 Years
Last updated on clinicaltrials.gov in January 2026.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.